Germline BRCA2 mutations in men with breast cancer

E Mavraki, IC Gray, DT Bishop and NK Spurr

1Imperial Cancer Research Fund, Genetic Epidemiology, Ashley Wing, St James’s Hospital, Beckett St, Leeds LS9 7TF, UK; 2Imperial Cancer Research Fund, Applied Development Laboratory, Dominion House, 59 Bartholomew Close, London EC1A 7BE, UK; 3SmithKline Beecham Pharmaceuticals, Biopharmaceutical Research & Development, New Frontiers Science Park, Harlow, Essex CM19 5AW, UK

Summary Breast cancer in men is rare and is clearly due in some cases to an inherited predisposition. A total of 28 male breast cancer patients were tested for BRCA2 mutations; two frameshifts and one putative missense mutation were identified. One of the frameshifts was detected in the same position as a mutation estimated to be responsible for 40% of all male breast cancer cases in Iceland.

Keywords: BRCA2, male breast cancer; mutation

It is estimated that 5–10% of female breast cancer cases are due to inheritance of autosomal dominant susceptibility genes (Claus et al, 1991). Two such genes, BRCA1 and BRCA2, localized to 17q and 13q12–13 respectively, have recently been identified (Miki et al, 1994; Wooster et al, 1995). Germline mutations in either of the two genes confers an 80–90% lifetime risk of breast cancer in women and an increased risk of ovarian cancer (Wooster et al, 1994). BRCA1 is estimated to account for approximately one-half of all highly penetrant dominant breast cancer families and the majority of families with cases of female breast and ovarian cancer (Easton et al, 1993) but, according to both linkage and mutation studies, does not account for a significant proportion of families with cases of male breast cancer (Stratton et al, 1994; Strewing et al, 1995a). Unlike BRCA1, a considerable number of BRCA2 mutations have been reported in heritable cases of male breast cancer (Wooster et al, 1995; Couch et al, 1996; Phelan et al, 1996; Tavtigian et al, 1996; Thorlacius et al, 1996; Friedman et al, 1997).

To determine the frequency of BRCA2 germline mutations in men with breast cancer, we have screened DNA from 26 affected men plus two women with early-onset breast cancer who had an affected male relative.

MATERIALS AND METHODS

DNA samples

Blood samples were drawn from breast cancer-affected individuals from a case–control study of male breast cancer conducted in the Yorkshire Trent and North-West regions of the UK. Genomic DNA was extracted from blood using standard procedures. DNA samples were available from 26 male patients and two affected female patients who had male relatives with breast cancer.

BRCA1 185delAG mutation screen

The DNA samples were tested for the 185delAG mutation in the BRCA1 gene by polymerase chain reaction (PCR) amplification.

RESULTS

Before BRCA2 screening, all 28 individuals were tested for 185delAG in BRCA1, as this mutation has been identified in three breast and breast/ovarian cancer families from the same geographical area (northern England). It should be noted that, although this mutation is common in Ashkenazi Jews (Struwing et al, 1995b), haplotype analysis suggests that none of the three families mentioned here are of Ashkenazi Jewish descent (D Kelsall, personal communication). All individuals in this study were found to be negative for this deletion (data not shown) and subsequently were screened for BRCA2 mutations. BRCA2 consists of 26 exons spanning 10 254 bp (Tavtigian et al, 1996). Three mutations were detected (Figure 1). DNA from individual MB1 has a single A insertion in a run of seven As in exon 24. In individual MB2, PCR fragments were run on a 6% non-denaturing acrylamide gel and visualized by UV transillumination following ethidium bromide staining.

Polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP) analysis and sequence analysis

PCR amplification of 200 to 300-bp DNA fragments covering the entire BRCA2 coding region was performed with a set of 62 pairs of primers designed by Dr Richard Wooster (personal communication; primer sequences available on request). Six of the 62 BRCA2 PCR products from each individual were pooled and run on 0.5 × MDE (Flowgen) gels in 0.6 × TBE. After electrophoresis, fragments were transferred to a nylon membrane (HybondN+, Amersham) and hybridized with radioactively end-labelled PCR primers. After hybridization, SSCP conformers were detected by autoradiography. All variant products identified were reamplified from genomic DNA, and sequenced using a 377 DNA sequencer (Applied Biosystems).
BRCA2 mutations in male breast cancer

Figure 1  Germline BRCA2 mutations in breast cancer-affected men. SSCP profiles are shown on the left, with band shifts due to the mutant alleles arrowed. Two normal profiles are shown in each case for comparison. Corresponding sequence electropherogram traces are shown on the right. Individuals MB1 and MB2 have frame-shift mutations due to an 'A' insertion and an 'AA' deletion respectively. Individual MB3 has an A→G transition.

- A 2-bp amino acid deletion was detected in exon 9. These mutations cause frameshifts predicted to result in premature termination of translation. A putative missense mutation was detected in DNA from individual MB3. This consists of an A→G transition in codon 2247 of exon 11 causing the amino acid substitution serine to glycine. The functional significance of this amino acid change is unknown. To determine if this variant is simply a common polymorphism, 34 further individuals were tested for this transition by SSCP analysis and no positives were identified. None of these three BRCA2 mutations had previously been reported (Wooster et al, 1995; Couch et al, 1996; Foster et al, 1996; Goggins et al, 1996; Lancaster et al, 1996; Miki et al, 1996; Neuhausen et al, 1996; Phelan et al, 1996; Takahashi et al, 1996; Tavtigian et al, 1996; Teng et al, 1996; Thorlacius et al, 1996; Weber et al, 1996; Gayther et al, 1997; the BIC database). No further frameshift or missense mutations were identified; however, a polymorphic SSCP conformer was detected in 12 of the 28 individuals. Direct sequencing characterized it as a silent A→G base substitution in codon 1132 of exon 11. This polymorphism has been reported previously (Phelan et al, 1996). These sequence variants are summarized in Table 1.

DISCUSSION

In this study, four variant conformers were identified, one of which is clearly a polymorphism. Of the remaining alterations detected, two cause a frameshift predicted to result in a truncated protein. The third sequence variant, consisting of an A→G transition in codon 2247 of exon 11, causes the amino acid substitution serine to glycine, which is of unknown functional significance.
The presence of this sequence alteration in the tumour of patient MB3 could not be determined because of the lack of archival material, and no DNA was available from other family members to confirm segregation with the disease. Failure to detect this variant in 34 additional individuals tested strengthens the argument for a deleterious effect in this breast cancer-affected individual. However, serine → glycine is a conservative amino acid change and the amino acid at this position is poorly conserved between human and murine BRCA2 sequences (Connor et al, 1997).

Both of the frameshift mutations and the putative missense mutation identified in this study are novel and occurred in three different exons (9, 11 and 24) of the BRCA2 gene. However, the 2-bp amino acid deletion detected in patient MB2 has occurred in the same position of exon 9 as the 999del5 mutation, which accounts for 40% of all male breast cancer patients in Iceland (Thorlacius et al, 1996). This suggests that mutations in codon 258 of the BRCA2 gene could be associated with increased susceptibility to male breast cancer.

The 28 breast cancer patients screened for germline BRCA2 mutations were selected without any initial regard for family history or age at onset. However, information on family history was available for all of the individuals included in this study: four patients had at least two additional cases of breast cancer in their families, five individuals had families with a single further case of breast cancer and one patient had one relative with breast and one with ovarian cancer. The remaining patients had no reported family history of breast or ovarian cancer. However, these individuals had recorded incidences of other cancers in their families, including colon, stomach, bladder, cervical and throat cancer. Some family history is known for the three individuals with BRCA2 mutations. Individual MB2 developed breast cancer at the age of 68 and has two male and two female affected relatives. Patients MB1 and MB3, with an age of incidence of 65 and 64 years respectively, have no known family history of breast or ovarian cancer. However, other malignancies have been reported in these two families, including sarcoma, cervical and stomach cancer. Our data, together with previous reports, suggest that BRCA2 could be involved in other forms of cancer in addition to breast cancer (Goggins et al, 1996; Berman et al, 1996; Couch et al, 1996; Phelan et al, 1996; Thorlacius et al, 1996). To investigate this possibility, mutation analyses on tumour cancers from other malignancies in families with germline BRCA2 mutations are required.

The frequency of BRCA2 mutations detected (2 or 3 out of 28, or 7–11%) is in good agreement with a previous study (Couch et al, 1996). The low number of mutations identified could be explained by the existence of non-coding mutations that are not covered by this approach. Furthermore, some mutations may remain undetected by SSCP. Although the sensitivity of this method is high, it depends largely on the electrophoretic conditions, the gel concentration and the size of the DNA fragments examined (Sheffield et al, 1993; Ravnik-Glavac et al, 1994). Alternatively, mutations in other genes, acquired either somatically or in the germline, may be responsible for some instances of male breast cancer. The identification of such genes coupled with more sensitive mutation detection systems should help to provide a better understanding of the genetic mechanisms underlying breast cancer.

ACKNOWLEDGEMENTS

This work was supported by the Imperial Cancer Research Fund. We thank the Yorkshire Cancer Organisation for supplying information on the male breast cancer cases, A Williams, S Thistlethwaite, B Ward, M Alcock and S Haynes for collecting the samples, Dr David Snary for providing laboratory space for some of this work, Professor Sue Povey for helpful discussions and a critical reading of the manuscript and Iain Goldsmith and colleagues for oligonucleotide synthesis.

REFERENCES

Berman DB, Costalas J, Schultz DC, Grana G, Daly M and Godwin AK (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56: 3409-3414
Claus EB, Risch N and Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J Hum Genet 48: 232-242
Connor F, Smith A, Wooster R, Stratton M, Dixon A, Campbell E, Tait TM, Freeman T, Ashworth A (1997) Cloning, chromosomal mapping and expression pattern of the mouse BRCA2 gen. Hum Mol Genet 6: 291-300
Couch FJ, Farid LM, DeShano ML, Tavignian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S and Weber BL (1996) BRCA2 germline mutations in male breast cancer case and breast cancer families. Nature Genet 13: 123-125
Easton DF, Bishop DT, Ford D and Crockford GP. The Breast Cancer Linkage Consortium. (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52: 678-701
Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BA and Gayther SA (1996) Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56: 3622-3625
Friedman LS, Gayther SA, Kurotski T, Gordon D, Noble B, Casey G, Ponder BAJ, Anton-Culver H (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60: 313-319
Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BAJ, Stratton MR, Easton D (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genet 15: 103-105
Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH and Kern SE (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360-5364
Jacobson LM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, LC, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR and Futreal PA (1996) BRCA2 mutations in primary breast and ovarian cancers. Nature Genet 13: 238-240
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenbal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayanandh P, Ward J, Tonin P, Narod S, Bristow FK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis S, Neuhausen S, Cannon-Albright L, Golgar D, Wiseman R, Kamb A and Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71

Miki Y, Katagiri T, Kasumi F, Yoshimoto T and Nakamura Y (1996) Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet 13: 245–247

Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnik M, Shattuck-Eidens D, Jhanwar S, Goldgar D and Offit K (1996) Recurrent BRCA2 16174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet 13: 126–128

Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod S and Futreal PA (1996) Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 13: 120–122

Ravnik-Glavac M, Glavac D and Dean M (1994) Sensitivity of single - strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet 3: 801–807

Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW and Stone EM (1993) The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16: 325–332

Stratton MR, Ford D, Neuhausen S, Seal S, Woozer R, Friedman LS, King MC, Egilsson V, Devilee P, McManus R, Daly PA, Smyth E, Ponder BAJ, Petro J, Cannon-Albright L, Easton DF and Golgar DE (1994) Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nature Genet 7: 103–107

Struweing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS and Tucker MA (1995a) Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57: 1–7

Struweing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC (1995b) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11: 198–200

Takahashi H, Chiu HC, Bandera CA, Bubshalt K, Liu PC, Cush FJ, Weber BL, LiWolski VA, Furuato M, Behane BA, Cardonick A, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC and Boyd J (1996) Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56: 2738–2741

Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, T.S., Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janekti T, Jiang P, Kehler R, Leblanc JF, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizinya H, Eyiford JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A and Golgar DE (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 12: 333–337

Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehler R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK and Kamb A (1996) Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nature Genet 13: 241–244

The Breast Cancer Information Core http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/

Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson NG, Tavtigian SV, Tulinius H, Ogmundsdottir HM and Eyiford JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet 13: 117–119

Weber BH, Brohm M, Stec I, Backe J and Caffier H (1996) A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 59: 962–964

Wooster R, Bignell G, Lancaster J, Swift S, Seal M, Mangion J, Collins N, Gregory S, Gumbs C, Micklen G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenc D, Keisler D, Ford D, Tonin P, Bishop DT, Spurr NC, Ponder BAJ, Eeles R, Petro J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A and Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ornston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Petro J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE and Florance A (1994) Localization of a breast cancer susceptibility gene BRCA2 to chromosome 13q12–13. Science 265: 2088–2090